
<rdf:RDF xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:svcs="http://rdfs.org/sioc/services#" xmlns:doap="http://usefulinc.com/ns/doap#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  
<ore:Aggregation rdf:about="https://phaidra.vetmeduni.ac.at/o:4995/#Aggregation">
  
<edm:aggregatedCHO rdf:resource="https://phaidra.vetmeduni.ac.at/o:4995"></edm:aggregatedCHO>

  
<edm:dataProvider>University of Veterinary Medicine Vienna</edm:dataProvider>

  
<edm:isShownAt rdf:resource="https://phaidra.vetmeduni.ac.at/o:4995"></edm:isShownAt>

  
<edm:isShownBy rdf:resource="https://phaidra.vetmeduni.ac.at/api/object/o:4995/get"></edm:isShownBy>

  
<edm:object rdf:resource="https://phaidra.vetmeduni.ac.at/api/object/o:4995/thumbnail"></edm:object>

  
<edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/4.0/"></edm:rights>

  
</ore:Aggregation>

  
<edm:ProvidedCHO rdf:about="https://phaidra.vetmeduni.ac.at/o:4995">
  
<dc:title xml:lang="en">Gel Electrophoretic Detection of Black Market ACE‐031</dc:title>

  
<dc:description xml:lang="en">The usage of ACE-031 (Ramatercept), a dimeric fusion protein consisting of a human activin receptor IIB (ACVR2B) fragment linked to an Fc-part of human IgG1, is banned according to chapter S4.3 of the “WADA 2024 List of Prohibited Substances and Methods” due to its potential performance enhancing properties. While ACE-031 has not yet been pharmaceutically approved, it is sold as research chemical on the “black market” (BM). The article presents a study on BM ACE-031 products and its detection by gel-electrophoresis and Western blotting. Of 14 tested products, only 12 contained an ACVR2B-immunoreactive protein. Electrophoretic separation by SDS-PAGE also showed that the 12 ACVR2B-products contained many other proteins in addition to the main compound (ca. 58.4 kDa). Further analyses by mass spectrometry and immunoblotting revealed that the 12 products contained the full-length human activin receptor IIB instead of ACE-031. The absence of an Fc-fusion protein was further confirmed by treatment with IdeS protease, which was unable to cleave the BM products. In addition, it was demonstrated that the protocol we developed to detect luspatercept (another ACVR2B-Fc fusion protein) in human serum could also be successfully applied for the detection of BM ACE-031. Because administering black market products to human subjects was not ethically justifiable, a study was conducted with rats. In rat serum, BM ACE-031 was detectable up to 48 h post administration. However, due to the relatively high dose applied (10 mg/kg body weight) and possible differences in metabolism, the detection window may be different in humans.</dc:description>

  
<dc:identifier rdf:resource="https://phaidra.vetmeduni.ac.at/o:4995"></dc:identifier>

  
<dc:language>en</dc:language>

  
<edm:type>TEXT</edm:type>

  
<dc:type>journal article</dc:type>

  
<dc:type>Wissenschaftlicher Artikel</dc:type>

  
<dc:type>Articolo di rivista</dc:type>

  
<dc:type xml:lang="de">Text</dc:type>

  
<dc:type xml:lang="de">Wissenschaftlicher Artikel</dc:type>

  
<dc:type xml:lang="en">Text</dc:type>

  
<dc:type xml:lang="en">journal article</dc:type>

  
<dc:type xml:lang="it">Documento PDF</dc:type>

  
<dc:type xml:lang="it">Articolo di rivista</dc:type>

  
<dc:subject xml:lang="en">ACE-031</dc:subject>

  
<dc:subject xml:lang="en">Black Market</dc:subject>

  
<dc:subject xml:lang="en">Doping</dc:subject>

  
<dc:subject xml:lang="en">Myostatin</dc:subject>

  
<dc:subject xml:lang="en">SDS-PAGE</dc:subject>

  
<dcterms:issued>2025</dcterms:issued>

  
<dc:date>2025</dc:date>

  
<dc:creator>Christian Reichel (Doping Control Laboratory Seibersdorf, Seibersdorf Labor GmbH, Seibersdorf, Austria)</dc:creator>

  
<dc:creator>Thomas Filip</dc:creator>

  
<dc:creator>Günter Gmeiner (Doping Control Laboratory Seibersdorf, Seibersdorf Labor GmbH, Seibersdorf, Austria)</dc:creator>

  
<dc:creator>Mario Thevis (European Monitoring Center for Emerging Doping Agents, German Sport University Cologne, Cologne, Germany)</dc:creator>

  
<dc:publisher>Wiley</dc:publisher>

  
<dcterms:isPartOf></dcterms:isPartOf>

  
</edm:ProvidedCHO>

  
<edm:WebResource rdf:about="https://phaidra.vetmeduni.ac.at/api/object/o:4995/get">
  
</edm:WebResource>

  
</rdf:RDF>